ArticleHuman vaccines & immunotherapeutics2016
Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- B cell-expressed CD1d promotes MPL/TDCM lipid emulsion adjuvant effects in polysaccharide vaccines.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Immunizing hearts: exploring the vaccination frontier in heart failure management.Annals of medicine and surgery (2012) · 2024Review
- Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.Human vaccines & immunotherapeutics · 2021Article
- Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients.Transplantation direct · 2020Article
- Influence of immune aging on vaccine responses.The Journal of allergy and clinical immunology · 2020Review
- Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.Expert review of vaccines · 2019Review
- An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.The Journal of infectious diseases · 2019Article
- Decision-making for PCV in adults.Human vaccines & immunotherapeutics · 2019Article
- Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases.Human vaccines & immunotherapeutics · 2019Article
- [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations].Atencion primaria · 2018Observational
- Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.Human vaccines & immunotherapeutics · 2018Article
- Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.BMC infectious diseases · 2018Article
- Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study.BMC public health · 2017Article
- Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.Human vaccines & immunotherapeutics · 2016Article
- What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?Human vaccines & immunotherapeutics · 2016Article
- Other age groups than children need to be considered as carriers of Streptococcal pneumoniae serotypes.Human vaccines & immunotherapeutics · 2016Article
- Pneumococcal conjugate vaccine in adults: Let's see what happens.Human vaccines & immunotherapeutics · 2016Article
- Reply to Dr. Peter Paradiso.Human vaccines & immunotherapeutics · 2016Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Advisory Committee on Immunization Practices of the US Centers for Disease Control (ACIP) has recently recommended the 13-valent protein-conjugate pneumococcal vaccine (PCV13) for routine use in adults age 18-65 who have immunocompromising conditions as well as in all adults over the age of 65. By comparison to 23-valent pneumococcal polysaccharide vaccine (PPSV23), antibody responses to PCV13 are similar or modestly better one month after vaccination. The implication that PCV13 will provide more persistent immunity has been disproven; 12 months later, recipients of PPSV23 or PCV13 have identical anti-pneumococcal activity. The theoretical concept that a protein-based vaccine will be followed by a booster effect when pure polysaccharide antigens are administered is based on remarkably little evidence. The strongest objection to the current recommendations is that, since PCVs stimulate mucosal antibodies, the widespread use of these PCVs has led to a near-disappearance of vaccine serotypes from the population. This phenomenon has been amply documented for PCV7, and PCV13 is well on its way to doing the same. Thus, as US physicians are convincing their adult patients to receive 2 "pneumonia shots" instead of one, the use of PCV13 in the USA is rapidly becoming irrelevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.